BD, BIOCORP Sign Agreement to Bring Connectivity, Traceability to Self-Administered Injectable Drugs

Rhea-AI Summary

BD (NYSE: BDX) has entered into a collaboration with Biocorp to enhance self-administered drug therapies through connected technology. The partnership aims to integrate Biocorp's Injay® technology with BD's UltraSafe Plus™ Passive Needle Guard, allowing biopharmaceutical manufacturers to capture and transmit injection data. This innovation is expected to improve patient adherence to injectable drugs. The connected drug delivery market is projected to grow significantly as digital technologies and self-administered therapies become more prevalent.

Positive

• Collaboration with Biocorp leverages connected technology to enhance self-administered drug therapies.
• Integration of Injay® technology with UltraSafe Plus™ Needle Guard improves patient adherence and data tracking.
• Growth potential in the connected drug delivery market, expected to witness double-digit growth rates.

Negative

• None.

Companies to Explore Opportunities to Integrate Biocorp’s Injay® Technology with BD UltraSafePlus™ Passive Needle Guard to Help Biopharmaceutical Manufacturers Capture and Transmit Self-Administered Injection Data.

FRANKLIN LAKES, N.J.--(BUSINESS WIRE)-- Regulatory News:

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Biocorp (Paris:ALCOR), a medical device and delivery systems manufacturer based in France, today announced that they have signed an agreement with the aim of using connected technology to track adherence for self-administered drug therapies, like biologics.

To support biopharmaceutical companies in their efforts to improve the adherence and outcomes of injectable drugs, the two companies will integrate Biocorp’s Injay® technology – a solution designed to capture and transmit injection events using Near Field Communication (NFC) technology – to the BD UltraSafe Plus™ Passive Needle Guard used with prefillable syringes.

“Connected drug delivery devices play an important role in helping biopharmaceutical manufacturers understand and track key trends in patient adherence,” said Matthew Schabacker, vice president and general manager of Advanced Drug Delivery Solutions at BD. “Our agreement with Biocorp enables us to explore innovative solutions in this market and further supports BD’s commitment to smart, connected care, enabling care to transition to alternate settings and improving chronic disease outcomes — as we combine Biocorp’s expertise in developing and commercializing connected drug delivery devices to our existing portfolio of advanced injection drug delivery systems.”

Biocorp’s Injay® is a simple and cost-effective connected solution designed to monitor the use of pre-fillable syringes in clinical studies or routine care. Through NFC technology and specific sensors to identify the product, it can confirm a complete injection and easily transfer that information to a smartphone.

“We are very proud to announce this collaboration with BD, a worldwide leader in pre-filled syringes and safety device market,” said Eric Dessertenne, CEO of Biocorp. “It shows the leading position of Biocorp in the field of smart drug delivery devices and addresses an unmet need in the market today.”

The increased prevalence of self-administered therapies for chronic diseases coupled with the pervasiveness of digital technologies in everyone’s life open new opportunities to improve outcomes and experience for patients and to increase the ability to monitor medication adherence.

The global connected drug delivery market is expected to grow at double digit growth rates¹ over the next decade – fueled by the transition from acute care settings to home care and the increased prevalence of self-administered therapies. Today, BD is a world leader in supplying prefillable syringes and safety systems to the biopharmaceutical industry – with approximately 70 percent of the top 100 biopharmaceutical companies using BD devices, and more than one billion BD UltraSafe™ units² sold since 2010 being used to administer over 40 different drugs.³

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 75,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.

About Biocorp

Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This smart sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of patients with diabetes. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 75 employees. BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR). For more information, please visit www.biocorpsys.com.

¹ Grandview Research CDDD Market, Data Bridge Market Research Global CDDD Market
² As of 2020
³ Drug products approved with BD UltraSafe™ solutions. Includes both BD UltraSafe Passive™ and BD UltraSafe Plus™ passive needle guards

View source version on businesswire.com: https://www.businesswire.com/news/home/20221017006035/en/

BD

Media:

Trey Hollern

Director, Public Relations

862.284.8629

trey.hollern@bd.com

Investors:

Francesca DeMartino

SVP, Head of Investor Relations

201.847.5743

Francesca.demartino@bd.com

BIOCORP

Sylvaine Dessard

Marketing & Communication Director

rp@biocorp.fr

Bruno ARABIAN

barabian@ulysse-communication.com

+33 (0)6 87 88 47 26

Source: BIOCORP

FAQ

What is the agreement between BD and Biocorp about?

BD and Biocorp signed an agreement to integrate Biocorp's Injay® technology with BD's UltraSafe Plus™ Needle Guard to track adherence for self-administered drug therapies.

How does Biocorp's Injay® technology work?

Injay® technology uses Near Field Communication (NFC) to capture and transmit injection events, confirming complete injections and transferring data to smartphones.

What is the significance of the BD and Biocorp collaboration for biopharmaceutical companies?

The collaboration aims to help biopharmaceutical manufacturers improve adherence and outcomes of injectable drugs by providing connected technology.

What is the projected growth of the connected drug delivery market?

The connected drug delivery market is expected to grow at double-digit rates over the next decade due to increased self-administered therapies and digital technology usage.

What market share does BD hold in the biopharmaceutical industry?

BD is a leader in supplying prefillable syringes and safety systems, with approximately 70% of the top 100 biopharmaceutical companies using BD devices.